RxSight, Inc. (RXST) AI Stock Analysis

RxSight, Inc. specializes in the development, manufacturing, and global distribution of light adjustable intraocular lenses (LAL) designed for cataract surgery. Originally established in 1997 as Calhoun Vision, Inc. and rebranded in February 2017, the Aliso Viejo, California-based company develops the RxSight system to enhance visual acuity post-surgery. Its proprietary RxSight light delivery device enables ophthalmologists to adjust the implanted LAL using targeted UV light exposure in an office-based setting. RxSight primarily serves cataract surgeons globally, providing customizable tools for personalized vision correction.

Between FY2021 and FY2024, annual revenue grew from $22.6M to $139.9M before declining 3.9% in FY2025 to $134.5M. Gross margin improved steadily over the same period, rising from 20.0% in FY2021 to 76.6% in FY2025. However, operating margin remained negative at -35.8% in FY2025, with net income of -$38.9M and an EPS of -$0.59. R&D expense increased each fiscal year, reaching $38.5M in FY2025. In the latest quarter ended June 30, 2026, quarterly revenue grew 0.3% year-over-year, while trailing twelve-month revenue reached $127.6M with an operating margin of -40.8%.

As of June 30, 2026, RxSight held $208.8M in cash and short-term investments against $10.6M in total debt, yielding net cash of $198.2M. Total assets stood at $352.7M and shareholders' equity was $263.3M, supported by a current ratio of 4.07 and a debt-to-equity ratio of 0.04. The company generated -$15.5M in operating cash flow and -$19.3M in free cash flow in FY2025. Capital expenditures totaled $3.8M in FY2025, while the share count increased by 51.7% over five years.

RxSight trades at a forward P/E of 116.3x, compared to 17.3x for the median of its US-listed Healthcare peers. Its price-to-sales ratio is 1.5x, below the peer median of 4.1x, and its price-to-book ratio is 0.8x. Enterprise value stands at $3.9M, producing an EV-to-revenue ratio of 0.0x. Over the past year, the stock fell 46.8%, compared to a 16.8% gain for the S&P 500 (SPY). Over five years, the stock dropped 66.7% while the S&P 500 rose 83.0%.

Wall Street analysts cover RxSight with 1 Buy, 7 Holds, and 2 Sells. The mean price target is $7.57, representing an upside of 67.8% from the last close of $4.51. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $147.1M and an EPS of -$0.28. For the next fiscal year, 5 analysts estimate revenue of $149.2M and an EPS of -$0.68. RxSight beat EPS estimates in 3 of the last 4 quarters, with its next earnings date scheduled for November 4, 2026.

This page is an AI-written research summary of RxSight, Inc. (RXST). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RXST income statement, RXST balance sheet, RXST key metrics, RXST analyst forecast, RXST chart. See the RXST stock overview for the latest quote and news.